Eli Lilly and Co
Healthy Returns: Novo Nordisk’s head of research and development previews the first-ever obesity pill
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. We’re inching closer to having the first-ever needle-free weight loss drug. That’s thanks to Novo Nordisk, which expects a U.S. approval for its daily pill for chronic […]
Read More
Healthy Returns: Eli Lilly’s chief scientific officer breaks down the latest obesity pill data
The Eli Lilly headquarters in Indianapolis, Indiana, on Aug. 15, 2024. AJ Mast | Bloomberg | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Eli Lilly‘s closely watched obesity pill is inching closer […]
Read More
Stocks making the biggest moves midday: EchoStar, Brown-Forman, Semtech, Oklo and more
Check out the companies making the biggest moves midday: Semtech — The semiconductor maker rallied 17% on better-than-expected second-quarter results and strong third-quarter revenue guidance. The company posted a Q2 profit of 41 cents per share, excluding certain items, on revenue of $27.6 million. Analysts expected earnings of 40 cents per share on revenue of […]
Read More
Stocks making the biggest moves premarket: EchoStar, Eli Lilly, Advanced Micro Devices & more
Check out the companies making headlines before the bell. EchoStar — The telecommunications stock surged 66% after AT & T said it would buy some wireless spectrum licenses from EchoStar for $23 billion. AT & T said that the transaction should close sometime in mid-2026. Shares of AT & T were last trading less than […]
Read More
Eli Lilly’s weight loss pill orforglipron clears its latest trial, paving way for approval
Eli Lilly Biotechnology Center is shown in San Diego, California, U.S. March 1, 2023. Mike Blake | Reuters Eli Lilly on Tuesday said its daily weight loss pill helped patients with obesity and Type 2 diabetes shed weight in a late-stage trial, meeting the study’s main goal and clearing the way for the company to […]
Read More
A world on weight loss drugs: How GLP-1s are reshaping the economy
Eternalcreative | Istock | Getty Images Miracle drugs, obesity treatments and skinny jabs. Call them what you will, few drugs have had a more transformative effect on Wall Street and waistlines over recent decades than GLP-1s. Familiarly known under the brand names Wegovy and Zepbound, Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medication used to […]
Read More
Eli Lilly’s obesity pill remains a viable rival to Novo’s oral Wegovy despite data that underwhelmed investors
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly‘s stock is still recovering after the drugmaker released trial data earlier this month on its closely watched obesity pill that underwhelmed Wall Street. In a key late-stage trial, […]
Read More
CNBC’s UK Exchange newsletter: The price is REIT
This report is from this week’s CNBC’s UK Exchange newsletter. Each Wednesday, Ian King brings you expert insights on the most important business stories from the U.K. and other key developments you won’t want to miss. Like what you see? You can subscribe here. The dispatch Episodes in which the mighty KKR receives a bloody nose […]
Read More
FDA approves first-ever glucose monitoring system for weight loss from Signos
Woman with Signos wearable and app Source: Signos The Food and Drug Administration on Wednesday approved the first-ever glucose monitoring system specifically for weight loss from the startup Signos, establishing a new option for Americans to manage their weight. Current treatment options for losing weight – popular drugs like GLP-1s and surgical interventions – are […]
Read More
Viking Therapeutics shares fall more than 30% on disappointing obesity pill trial data
Shares of Viking Therapeutics fell more than 30% in premarket trading Tuesday after the company released mid-stage trial data on its obesity pill that disappointed investors. The results could be a blow to Viking, which was once seen as a hot M&A target as pharmaceutical companies scramble to join the booming market for obesity and […]
Read More